entertainment -WSS

entertainment

author：knowledge 2025-08-25 07:28:24 - browse：95

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Congress might make insulin pumps more accessible to the blind

WSS

Medicare Advantage's lean provider networks lead CMS complaints

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Websites selling Wegovy, Zepbound ingredients targeted by FDA

ASCO Takeaways: Winners, snoozers, and the art of cancer care

An outdated Medicare rule harms dementia patients with anxiety

hotspot

entertainment

leisure time

Psychedelics group wrestles with new pharma identity

Having children helps parents live longer, especially after age 80

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Congress might make insulin pumps more accessible to the blind

After affirmative action ruling, medical educators look to 'holistic review'

Artificial intelligence use in health care faces greater scrutiny in 2024

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

An outdated Medicare rule harms dementia patients with anxiety

How to save PrEP access — and even expand it

Abbott's new heart device gets FDA advisory panel nod

hotspot

An outdated Medicare rule harms dementia patients with anxiety

Senators tussle over abortion against the backdrop of a presidential campaign

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Juul documents reveal insider tactics on political lobbying

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Finland to offer bird flu vaccine to select groups of people, a possible global first

knowledge

focus

Wikipedia

focus